<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94149">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972555</url>
  </required_header>
  <id_info>
    <org_study_id>CMILE</org_study_id>
    <nct_id>NCT01972555</nct_id>
  </id_info>
  <brief_title>Cardiac Function After Minimally Invasive Aortic Valve Implantation</brief_title>
  <acronym>CMILE</acronym>
  <official_title>Single-center Randomized Controlled Trial of Cardiac Function After Minimally Invasive Aortic Valve Implantation (CMILE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized controlled trial. Patients scheduled for
      aortic valve replacement (AVR) at Karolinska University Hospital in Stockholm, Sweden will
      be eligible. Forty patients will be randomly assigned to either minimally invasive (20
      patients) or conventional AVR (20 patients). CE-marked and FDA-approved mechanical and
      bioprosthetic aortic valves (conventional stented or sutureless bioprostheses) will be
      implanted. Transthoracic echocardiography will be performed before surgery, and at day 1, 4,
      and 40. Echocardiographic parameters as well as preoperative clinical characteristics and
      postoperative clinical outcomes will be registered. Routine blood sampling will be performed
      pre- and postoperatively. All available data will be collected prospectively. Informed
      consent will be obtained from patients meeting the inclusion criteria before the initiation
      of any study-specific procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tricuspid Annular Peak Systolic Excursion (TAPSE)</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Right ventricular fractional area change</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Right ventricular dimensions</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Diastolic left ventricular function</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary bypass time</measure>
    <time_frame>Peroperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aortic cross-clamping time</measure>
    <time_frame>Peroperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assisted ventilation time</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Paravalvular leakage</measure>
    <time_frame>Postoperatively at day 1, 4, and 40</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New onset atrial fibrillation</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Implantation of permanent pacemaker</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Permanent cerebrovascular accident</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transient  cerebrovascular accident</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemodialysis</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary complication</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Chest tube output 12 hours after surgery</measure>
    <time_frame>12 hours after wound closure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reexploration for bleeding</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reoperation for sternal wound complication</measure>
    <time_frame>30 days after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Packed red blood cells</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative in-hospital length of stay</measure>
    <time_frame>During hospital stay, an expected average of 6 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular ejection fraction (Simpson's biplane)</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular end-diastolic volume (Simpson's biplane)</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Annular Peak Systolic Excursion (MAPSE)</measure>
    <time_frame>Preoperatively and postoperatively at day 1, 4, and 40</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>Minimally invasive aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive aortic valve replacement</intervention_name>
    <arm_group_label>Minimally invasive aortic valve replacement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional aortic valve replacement</intervention_name>
    <arm_group_label>Conventional aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Severe aortic stenosis defined as aortic valve area of less than 1 cm2 or index area
             of 0.6 cm2/m2 by echocardiography

          -  Referred for medically indicated aortic valve replacement

          -  Sinus rhythm

          -  Provide written informed consent

        Exclusion Criteria:

          -  Left ventricular ejection fraction less than 0.45

          -  Presence of any coexisting severe valvular disorder

          -  Previous cardiac surgery

          -  Urgent or emergent surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Sartipy, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reidar Winter, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Svenarud, MD, PhD</last_name>
    <phone>+46 (0) 8 517 708 12</phone>
    <email>peter.svenarud@karolinska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Svenarud, MD, PhD</last_name>
      <phone>+46 (0) 8 517 708 12</phone>
      <email>peter.svenarud@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Peter Svenarud, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrik Sartipy, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Liska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magnus Dalén, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Franco-Cereceda, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reidar Winter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magnus Bäck, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Oliveira Da Silva, MLS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Svenarud</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
